Subject Index 433 colour, 30-34 FADU tumour cells, 19-20 Hamman’s syndrome, 355-356 vibrometer, 22-24 Fast spin echo (FSE), 310-315 Head and neck Drainage, 36-39 Fat graft myringoplasty, 44-47 cancer, 77-82, 88-95, 102-106 Dyslexia, 305-309 FESS. See Functional endoscopic sinus free flaps, 249-254, 361-364 Dysphagia, 32we7 -331 surgery neoplasms, 395-402 Dysthyroid orbitopathy, 242-24 Fibrin glue, 36-39 rhabdomyosarcoma, 53-58 FLAIR. See Fluid-attenuated inversion EAC. See External auditory canal recovery aed squamous cell carcinoma, 8-11] Ear Flap surgery, 139-140, 209-214 asymmetry, 133-137 free, 102-106, 249-254, 361-364 trauma, 380-383 discharging, 384-386 pectoralis major myocutaneous, 102 tumour, 53-58 inner, 310-315 106 See also Neck neoplasm, 387-393 pedicled, 102-106 Hearing See also Hearing loss; Middle ear retraction, 139-140 screening, 133-137 EBV. See Epstein-Barr virus Fluid-attenuated inversion recovery sensitivity, 343-347 Elderly, 8-11 FLAIR), 310-315 See also Hearing loss Electrocautery, 180-185 Foreign body Hearing loss Electrohydraulic extracorporeal shock aminoglycoside-induced, 71-74, 153 aerodigestive tract, 216-221 wave lithotripsy, 320-325 156 otitis externa from, 278-280 ELSTs. See Endolymphatic sac tumours Fractures See also Sensorineural hearing loss Emphysema, 355-356 Heart rate, 338-341 Endolymphatic sac tumours (ELSTs), 387 orbital floor, | Hemangioendothelioma, 194-195 393 temporal bone, 380-383 Hemangioma, 196-199 Endoscopic sinus surgery FRD. See Frontal recess dissection Hemangiopericytoma (HP), 141-143 antrochoanal polyps, 423-426 Free flaps (FRFs), 102-106, 249-254, 361 Hemithyroidectomy, 209-214 frontal sinus, 261-269 364 Hemorrhage, 310-315 maxillary sinus atelectasis and ‘silent Free radicals, 153-156 High-frequency audiometry, 343-347 FRFs. See Free flaps sinus syndrome, 60-64 HIV (human immunodeficiency virus), sinonasal lesions, 27 0 907 Frontal recess dissection (FRD), 261-269 205 See also Functional endoscopic sinus Frontal sinusitis, 261-269 Hospital admission, 235-241 Frozen section, 292-303 HP. See Hemangiopericytoma surgery FSE. See Fast spin echo Human immunodeficiency virus. See HIV Endoscopy, l Functional endoscopic sinus surgery Hyperthermia, 186-188 EORTC. See European Organisation for FESS Hypertrophy Research and Treatment of Cance1 I computer assisted, 373-379 masseteric muscle, 40-42 nasal polyposis, 122-131 tonsillar, 270-274 Epithelioid hemangioendothelioma, 194 Hypopharyngeal squamous cell carci 195 Gender, 133-137 noma, 108-110 Epstein-Barr virus (EBV), 147-150 Gentamicin, 153-156 Hypopharyngeal stricture, 327-33 Esophageal stricture, 327-331 Gentian violet, 384-386 ESWL. See Extracorporeal shock wave Germline mutation, 387-393 IAC. See Internal auditory canal lithotripsy Giant multinodular goitre, 199-202 1LO292 Otodynamics Analyzer, 133-137 Ethnic populations, 249-254 ; Glande parotide, 189-191, 317-319 IMT. See Inflammatory myofibroblastic European Organisation for Research and Glass discs, 292-303 tumour lreatment of Cancer (EORTC), 332 Glaucoma, 30-34 Infants, 133-137 336 Glottic carcinoma, 416-421 Inflammation, 202-204, 310-315 Exophthalmos, 242-247 Glue, 36-39 Inflammatory myofibroblastic tumour External auditory canal (EAC), 278-280 Goblet .cells, 122-131 (IMT), 202-204 External jugular vein, 361-364 Goitre, 199-202 Infratemporal tumours, 173-178 Extracorporeal shock wave lithotripsy Goode T-Tube, 287-291 Inner ear, 310-315 ESWL), 320-325 Gratt, 44-47 Internal auditory canal (IAC), 310-315 Graves’ ophthalmopathy, 242-247 Intraocular pressure, 30-34 Facial skin color, 249-254 Group A Streptococcus, 65-67 Irradiation, 332-336 434 The Journal of Otolaryngology, Volume 35, Number 6 , 2006 Ischemia, 408-410 magnetic resonance imaging of, 13-18 Oropharynx, 404-407 Middle turbinate resection (MTR), 261- Ossicular replacement prostheses, > 24 Jugular vein, 361-364 269 Otitis, 384-386 Midface degloving, 275-277 Otitis externa, 278-280 Killian polyp, 423-427 Mohs surgery, 292-320/3\2 Otitis media (OM) Kimura’s disease, 358-360 Mould, 292-303 chronic suppurative, 44-47 Klebsiella rhinoscleromatis, 206-207 Mouse studies, 97-100, 153-156, 157-165 with effusion, 287-291 Kyste hydatique, 317-319 MRI. See Magnetic resonance imaging silent, 278-280 MRSA. See Methicillin-resistant See also Chronic otitis media Labyrinth diseases, 387-393 Staphylococcus aureus Ototoxicity Labyrinthine concussion, 380-383 MTR. See Middle turbinate resection cisplatin, 19-20, 112-116 Labyrinthine hemorrhage, 310-315 Musical perception, 343 347 gentamicin, 153-156 Lambeau myo-muqueux de buccinateur en Musical training, 343-347 ilot, 404-407 Myiasis, 192-193 Oxymetazoline, 30-34 Laryngeal squamous cell carcinoma, 108 Myocardial infarction, 408-410 Paediatrics. See Children 110 Myofibroblastic tumour, 202-204 Pain Laser Doppler vibrometer, 22-24 Myringoplasty Leukotriene receptor antagonist, 117-120 postoperative, 167-171 fat graft, 44-47 Level | neck lymph nodes, 108-110 throat, 408-410 transtympanic, 411-415 Lingual tonsillitis, 65-67 Papillary thyroid adenocarcinoma (PTA), Lipoma, 7 429 Myringotomy, 287 291 366-372 Lithiasis, 320-325 Papilloma, 275-277 Nasal cytology, 255-259 Lithotripsy, 320 Parameningeal rhabdomyosarcoma, 53-58 Nasal obstruction, 83-86 Lymph nodes, 108-110 Paranasal sinuses, 147-150 Nasal polyposis, 122 131 Lymphoepithelioma, 147-150 Parkinson’s disease (PD), 349-353 Nasal rhinoscleroma, 206-207 Parotidectomy, 36-39 Nasal spray, 30-34 Macroglobulinemia, 68-70 Parotid gland, 189-191, 317-319 Nasal valves, 83-86 Magnesium, 112-116 Partial ossicular replacement prosthesis Nasophary ngeal carcinoma, 17-150 Magnetic resonance imaging (MRI) (PORP), 22-24 Nasopharyngeal stenosis, 430-431 mastoid cavity and middle ear, 13-18 PD. See Parkinson’s disease Nasopharyngeal tumours, 173-178 Pectoralis major myocutaneous flap in sudden sensorineural hearing loss, Neck (PMMP), 102 106 310-315 lymph nodes, 108-110 Pedicled flap, 102-106 Malignant hyperthermia (MH), 186-188 See also Head and neck Perennial allergic rhinitis, 117-120 Mandible, 202-204 Neoplasms Permeatal route, 411 115 Masseteric muscle hypertrophy, 40-42 Plasma cell neoplasm, 68 70 Mast cells, 122-131 head and neck, 395-402 Platinum, 19-20 Mastoid cavity, 13-18 Mastoidectomy, 48-52 plasma cell, 68-70 PMMEF. See Pectoralis major myocuta neous flap Mastoiditis, 278-280 thyroid, 209-214 Pneumomediastinum, 355-356 Maxillary sinus Newborn, 133-137 Polyposis, 261-269 atelectasis, 60-64 Nondysphonic Parkinson’s disease, 349 Polyps 353 polyp, 423-426 Nucare program, 88-95 antrochoanal, 423-426 Meniere's disease, 26-29 nasal, 122-131 Metastasis Oncocytic carcinoma, 189-191 PORP. See Partial ossicular replacement brain, 366-372 Oncocytomas, 189-19] prosthesis cervical lymph node, 108-110 Oral cancer, 102-106, 157-165 Positive resection margin, 97-100 submandibular gland, 108-110 Oral squamous cell carcinoma, 102-106 Postoperative complications, 235-241 Methicillin-resistant Staphylococcus aureus Orbital decompression, 22 42-2 t1/7 Postoperative pain, 167 (MRSA), 384-386 Orbital floor fractures, | Postparotidectomy, 3 MH. See Malignant hyperthermia Orbital rhabdomyosarcoma, 53-58 Praat software, 349-353 Middle ear Orbitopathy, 242- 247 Pressure capillary hemangioma, 196-199 Oropharyngea! carcinoma, 102-106, 332- intraocular, 30-34 336 subglottic, 77-82 Subject Index 435 Proptosis reduction, 242-247 Silent sinus syndrome, 60-64 See also Endoscopic sinus surgery; Prostheses, 22-24 Sinonasal hemangiopericytoma, 141-143 specific procedures Proteomics, 157-165 Sinonasal papillomas, 275-277 Suturing, 77-82 Pseudomonas aeruginosa, 384-386 Sinonasal polyposis, 261-269 Swallowing, 77-82 Pseudostratified epithelium, 122-131 Sinus Sweet’s syndrome (SS), 144-147 Psychoeducational intervention, 88-95 frontal, 261-269 PTA. See Papillary thyroid adenocarci- Temporal bone paranasal, 147-150 noma basal cell carcinoma, 281-283 silent, 60-64 Pure-tone audiometry, 343-347 fracture, 380-383 See also Endoscopic sinus surgery; pathology, 387-393 QOL. See Quality of life Sinusitis TEOAEs. See Transient evoked otoacoustic Quality of life (QOL) Sinusitis emissions with and without computer assistance in children, 255-259 Thiosulfate, 19-20, 153-156 in sinus surgery, 373-379 frontal, 261-269 Throat pain, 408-410 with head and neck cancer, 88-95, 395- Skull base, 68-70, 173-178 Thyroglobulin, 366-372 402 Sneeze, 355-356 Thyroid SNHL. See Sensorineural hearing loss carcinoma, 209-214 in patients undergoing thyroid surgery, Snoring, 270-274 papillary adenocarcinoma, 366-372 209-214 in patients with oropharyngeal carci Sodium thiosulphate (STS), 19-20, 153- surgery, 209-214 156 Thyroidectomy, 209-214 noma, 332-336 Spindle cell lipoma (SCL), 427-429 Tisseel fibrin glue, 36-39 Squamous cell carcinoma (SCC) Tissue embedding, 292-303 Radiotherapy, 227-233, 332-336, 416-421 FADU tumour cells, 19-20 Tongue, 427-429 Receptor antagonist, 117-120 Reovirus, 97-100 glottic, 416-421 Tonsillar carcinoma, 227-233 Retrobulbar hemodynamics, 30-34 head and neck, 8-11, 102-106 Tonsillar hypertrophy, 270-274 Tonsillar tuberculosis, 205 Retrograde balloon dilation, 327-331 laryngeal and hypopharyngeal, 108-110 Tonsillectomy, 167-171, 180-185 Rhabdomyosarcoma (RMS), 53-58 oral and oropharyngeal, 102-106 Tonsillitis, 65-67 Rhinitis reovirus salvage of positive resection Tonsils, 167-171, 227-233, 270-274 allergic, 117-120 margin, 97-100 Tracheostomy, 77-82 nonallergic, 338-341 tonsillar, 227-233 Transconjunctival repair, 1-7 vasomotor, 338-341 SS. See Sweet’s syndrome rransient evoked otoacoustic emissions Rhinomanometry, 83-86, 117-120 SSNHL. See Sudden sensorineural hearing (TEOAEs) Rhinometry, 117-120 loss in newborns, 133-137 Rhinoscleroma, 206-207 Staphylococcus aureus, 384-386 in patients with urinary lithiasis, 320- Rhinosinusitis Stenosis, 327-331, 430-431 325 acute, 144-147 Stenting, 430-431 Transtympanic myringoplasty, 411-415 chronic, 373-379 Strictures, 327-331 rrauma, 380-383 RMS. See Rhabdomyosarcoma STS. See Sodium thiosulphate r-Tube, 287-291 Ropivacaine, 167-171 Subglottic pressure, 77-82 Tuberculosis, 205 Submandibular gland Tumours Scarring, 22-24 epithelial hemangioendothelioma, 194 in children, 53-58 SCC. See Squamous cell carcinoma 195 endolymphatic sac, 387-393 SCL. See Spindle cell lipoma Screening, 133-137 metastasis, 108-110 FADU cells, 19-20 Sensorineural hearing loss (SNHL) Subtemporal-preauricular approach, 173- head and neck, 53-58 concussion and, 380-383 178 inflammatory myofibroblastic, 202-204 Sudden sensorineural hearing loss gentamicin for, 153-156 infratemporal and nasopharyngeal, 173- (SSNHL), 71-74, 310-315 sudden, 71-74, 310-315 178 Surgery Seroma, 36-39 temporal bone, 387-393 ambulatory, 235-241 Serum proteomics, 157-165 See also Cancer; Carcinoma Shock wave lithotripsy, 320-325 head and neck, 139-140, 395-402 Tympanic membrane, 44-47 thyroid, 209-214 Tympanic perforation, 287-291 Silent otitis media, 278-280 versus radiotherapy, 416-421 Tympanoplasty, 222-225 436 The Journal of Otolaryngology, Volume 35, Number 6, 2006 Urinary lithiasis, 320-325 Voice, 349-353, 416-421 Well-differentiated thyroid carcinoma, Volumetric analysis, 1-7 209-214 Vasomotor rhinitis, 338-341 von Hippel-Lindau disease, 387-393 Wound drainage, 36-39 Verbal stimuli, 305-309 Vessel selection, 361-364 Waldenstrém’s macroglobulinemia, 68-70 Xenotransplantation, 163-164